Here are the 10-Q quarterly reports from Quest Diagnostics Inc. (DGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics reported third-quarter 2026 revenue of $3.097 billion, up 10.0% year over year. Net income attributable to Quest rose 27.6% to $312 million, diluted EPS increased 28.7% to $2.78, and operating income reached $479 million, up 24.2%.
Diagnostic information services (DIS) revenue rose 10.2%, primarily on organic growth. Requisition volume increased 14.5%, while revenue per requisition declined 4.2%, primarily reflecting the greater proportion of routine tests in new Corewell Health and Fresenius Medical Care relationships.
Quest completed its Corewell Health laboratory venture in January 2026, with 51% ownership; Corewell Health holds 49%. Consideration included $38 million in cash and a 49% noncontrolling interest valued at $253 million. A separate agreement to acquire select outreach lab assets in the Northeastern U.S. is expected to close later in 2026, subject to customary closing conditions. Nine-month operating cash flow was $1.486 billion versus $1.421 billion.
Quest Diagnostics reported strong Q2 2026 results, with net revenues of $3,043 million, up 10.2% from 2025, driven mainly by its Diagnostic Information Services business. DIS volume rose 13.1% (13.0% organic), helped by new relationships with Corewell Health and Fresenius Medical Care, while revenue per requisition declined 2.8% due to a higher mix of routine tests.
Net income attributable to Quest Diagnostics increased to $320 million and diluted EPS to $2.84 for the quarter; for the first half of 2026, net revenues were $5,938 million and diluted EPS $5.08. Operating margins remained in the mid-teens as higher compensation and supply costs were partially offset by the multi‑year Invigorate cost‑savings program. Cash generated from operating activities reached $875 million in the first half against capital expenditures of $252 million. The company ended June 30, 2026 with $626 million in cash and $5,642 million of long‑term debt after issuing $500 million of 5.00% senior notes due 2036 and repaying $500 million of 3.45% notes, and continued returning capital through $0.86 quarterly dividends and $100 million of share repurchases.
Quest Diagnostics grew solidly in early 2026. Net revenues for the quarter ended March 31, 2026 rose to $2,895 million from $2,652 million, driven mainly by its core diagnostic information services business.
DIS revenue increased 9.4% to $2,832 million as requisition volume grew 10.9%, helped by new relationships with Corewell Health and Fresenius Medical Care. Revenue per requisition fell 1.3% due to a higher mix of routine testing, but excluding these contracts it increased about 2.5%.
Net income attributable to Quest Diagnostics rose to $252 million from $220 million, and diluted EPS increased to $2.24 from $1.94. Operating income improved to $399 million from $346 million as cost savings from the Invigorate program helped offset higher compensation and supplies. Operating cash flow was $278 million versus $314 million, reflecting timing of receipts and higher bonus payments. The company invested $114 million in capital expenditures, continued a quarterly dividend of $0.86 per share, and ended the quarter with $393 million of cash and $5.2 billion of long-term debt.
Quest Diagnostics (DGX) reported higher Q3 2025 results. Net revenues rose to $2,816 million from $2,488 million a year ago, and diluted EPS increased to $2.16 from $1.99. Operating income grew to $386 million, while net income attributable to Quest reached $245 million. Cost of services and SG&A increased alongside revenue growth, and Q3 included $11 million of restructuring and impairment charges.
For the first nine months of 2025, revenue was $8,229 million and diluted EPS was $6.57. Operating cash flow was strong at $1,421 million, funding $369 million of capex, $263 million of dividends, and $150 million of share repurchases (0.9 million shares). Cash ended at $432 million; total assets were $16,197 million and stockholders’ equity was $7,295 million.
DGX repaid $600 million notes that matured in March 2025 and extended its $750 million revolver to April 2030, with a $500 million accordion. The company closed the purchase of select Spectra Laboratories clinical testing assets for $34 million and finalized LifeLabs purchase accounting. As of October 15, 2025, shares outstanding were 111,242,362.